Clinical Trial Results: In heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, the combination of MRT-2359 and enzalutamide achieved a 100% PSA response rate, highlighting the potential of this combination in a population with limited treatment options.
Disease Control Rate: Among patients with AR mutations, MRT-2359 demonstrated a 100% disease control rate, with all four patients showing PSA responses, indicating the drug's efficacy in specific patient subsets.
Favorable Safety Profile: The combination treatment exhibited primarily Grade 1-2 adverse events, suggesting that the use of MRT-2359 with enzalutamide is well-tolerated, which may facilitate its future clinical applications.
Future Research Plans: The company plans to initiate a new Phase 2 study in 2026 to further confirm the clinical activity of MRT-2359, with potential expansion into additional patient subsets, demonstrating a continued commitment to advancing prostate cancer treatment options.
GLUE
$18.665+Infinity%1D
Analyst Views on GLUE
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.450
Low
16.00
Averages
18.00
High
20.00
Current: 16.450
Low
16.00
Averages
18.00
High
20.00
Wells Fargo
Equal Weight -> Overweight
upgrade
$22
2025-12-16
New
Reason
Wells Fargo
Price Target
$22
2025-12-16
New
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target. The firm cites the company's catalyst path in 2026 for the upgrade. Wells sees upside from MRT-8102's Phase 1 update in the first half of 2026 and likely disclosure of Novartis' (NVS) plans for MRT-6160. The MRT-8102 Phase 1 update should be "de-risking," the analyst tells investors in a research note.
Wedbush
Robert Driscoll
Buy
Maintains
$15 → $17
2025-03-21
Reason
Wedbush
Robert Driscoll
Price Target
$15 → $17
2025-03-21
Maintains
Buy
Reason
Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.
Wells Fargo
Derek Archila
Hold
Maintains
$11 → $10
2025-03-21
Reason
Wells Fargo
Derek Archila
Price Target
$11 → $10
2025-03-21
Maintains
Hold
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Monte Rosa Therapeutics to $10 from $11 and keeps an Equal Weight rating on the shares. The firm likes the progress on MRT-6160 and believes it increases the odds of future milestones and royalties. That said, Monte Rosa Therapeutics' programs remain early and with limited catalysts in the near term, Wells expects shares to be range bound.
Wells Fargo
Derek Archila
Buy
to
Hold
Downgrades
$14 → $11
2024-12-19
Reason
Wells Fargo
Derek Archila
Price Target
$14 → $11
2024-12-19
Downgrades
Buy
to
Hold
Reason
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock's upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Phase 1 update in Q1 may have too few patients to fully interpret its profile. As such, Monte Rosa shares are likely to be range bound in 2025, the analyst tells investors in a research note.
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
